Overview

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Status:
RECRUITING

Trial end date:
2027-09-10

Target enrollment:

Participant gender:

Summary

This is a prospective, single-arm, multicenter, phase II clinical study designed to evaluate the initial efficacy and safety of patients receiving Tislelizumab in combination with recombinant human endostatin injection plus chemotherapy for stage III unresectable non-small cell lung cancer. To evaluate the surgical conversion rate of tirellizumab combined with recombinant human endostatin injection and chemotherapy induction therapy in patients with initially unresectable stage III non-small cell lung cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Hua Zhang

Treatments:

Drug Therapy
endostar protein
Endostatins
Surgical Procedures, Operative